|
1
|
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
|
Ann Intern Med
|
2011
|
4.21
|
|
2
|
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.
|
J Acquir Immune Defic Syndr
|
2006
|
1.01
|
|
3
|
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2010
|
0.87
|
|
4
|
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
|
Antimicrob Agents Chemother
|
2006
|
0.84
|
|
5
|
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
|
AIDS Res Hum Retroviruses
|
2009
|
0.83
|
|
6
|
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
|
BMC Infect Dis
|
2003
|
0.78
|
|
7
|
Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies.
|
HIV Clin Trials
|
2009
|
0.78
|
|
8
|
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.
|
HIV AIDS (Auckl)
|
2011
|
0.75
|
|
9
|
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
|
Antivir Ther
|
2008
|
0.75
|